Table 3 Median Survival Outcomes with BEV
From: Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Median Survival | 95% CI (55) | |
|---|---|---|
Overall Survival from Initial Diagnosis (n = 55) | 17.0 months | 14.8–19.2 months |
Progression Free Survival from Initial Diagnosis (n = 55) | 11.0 months | 9.0–13.0 months |
Overall survival from relapse (n = 48) | 6.0 months | 4.6–7.4 months |
Overall Survival from BEV decision-making (n = 43) | 4.0 months | 1.0–7.2 months |
Overall Survival from BEV decision-making with BEVstart (n = 28) | 6 months | 4.4–7.6 months |
Survival from BEV cessation (n = 28) | 30 days | 7–65 days |